In the case of oligorecurrent, hormone-sensitive prostate cancer (PCA), PSMA-targeted radioguided surgery (PSMA-RGS) has been proven effective for the removal of cancerous tissue achieving consecutive PSA responses [2].However, efficient biomarkers or imaging tools are still needed to identify patients who benefit most from this experimental procedure, and corresponding studies are ongoing (e.g., BioPoP, NCT04324983). The gene discussed is FOLH1; the disease is posterior cortical atrophy.